E. C. Yildirim Et Al. , "Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study," Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, 2023
Yildirim, E. C. Et Al. 2023. Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , (Barcelona, Spain).
Yildirim, E. C., Atag, E., Yuzugullu, E., Unal, O. U., Celebi, A., Keser, M., ... Uzun, M.(2023). Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study . Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain
Yildirim, E. Et Al. "Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study," Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 2023
Yildirim, E. C. Et Al. "Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, 2023
Yildirim, E. C. Et Al. (2023) . "Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain.
@conferencepaper{conferencepaper, author={E. Caliskan Yildirim Et Al. }, title={Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study}, congress name={Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)}, city={Barcelona}, country={Spain}, year={2023}}